Biotech · Private company · Morrisville, NC, US
Burleson Research Technologies, Inc.
Track this companyFree. Adds Burleson Research Technologies, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials0None registered
Pipeline programs0None found yet
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
NIH awards9
- STUDIES TO EVALUATE THE POTENTIAL FOR ENVIRONMENTAL&THERAPEUTIC AGENTS TO INDUCE IMMUNOTOXICITY - In vivoFiscal year 2026 · $8.3KNIH RePORTER 273201400017C-P00029-9999-2 · fetched Nov 12, 2026
- STUDIES TO EVALUATE THE POTENTIAL FOR ENVIRONMENTAL&THERAPEUTIC AGENTS TO INDUCE IMMUNOTOXICITY - In vitro immunomodulationFiscal year 2026 · $8.3KNIH RePORTER 273201400017C-P00029-9999-3 · fetched Nov 12, 2026
- Enabling risk-based testing through characterization of environmentally induced immune dysregulation and susceptibility to the SARS-CoV2 virus and COVID-19Fiscal year 2026 · $8.4KNIH RePORTER 273201400017C-P00029-9999-4 · fetched Nov 12, 2026
- STUDIES TO EVALUATE THE POTENTIAL FOR ENVIRONMENTAL&THERAPEUTIC AGENTS TO INDUCE IMMUNOTOXICITY - In vivoFiscal year 2025 · $100KNIH RePORTER 273201400017C-P00028-9999-2 · fetched Nov 12, 2026
- STUDIES TO EVALUATE THE POTENTIAL FOR ENVIRONMENTAL&THERAPEUTIC AGENTS TO INDUCE IMMUNOTOXICITY - In vitro immunomodulationFiscal year 2025 · $250KNIH RePORTER 273201400017C-P00028-9999-3 · fetched Nov 12, 2026
- Enabling risk-based testing through characterization of environmentally induced immune dysregulation and susceptibility to the SARS-CoV2 virus and COVID-19Fiscal year 2025 · $250KNIH RePORTER 273201400017C-P00028-9999-4 · fetched Nov 12, 2026
- STUDIES TO EVALUATE THE POTENTIAL FOR ENVIRONMENTAL&THERAPEUTIC AGENTS TO INDUCE IMMUNOTOXICITY - In vivoFiscal year 2024 · $830.2KNIH RePORTER 273201400017C-P00023-9999-2 · fetched Nov 12, 2026
- STUDIES TO EVALUATE THE POTENTIAL FOR ENVIRONMENTAL&THERAPEUTIC AGENTS TO INDUCE IMMUNOTOXICITY - In vitro immunomodulationFiscal year 2024 · $662.4KNIH RePORTER 273201400017C-P00023-9999-3 · fetched Nov 12, 2026
- Enabling risk-based testing through characterization of environmentally induced immune dysregulation and susceptibility to the SARS-CoV2 virus and COVID-19Fiscal year 2024 · $1.4MNIH RePORTER 273201400017C-P00023-9999-4 · fetched Nov 12, 2026